AOP Orphan
Manufacturing · Austria · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Wilhelminenstrasse 91/iif, Vienna, Vienn...Phone Number
+43 150372440Website
www.aoporphan.comRevenue
$69.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About AOP Orphan
AOP Health is a European pioneer in integrated therapies for rare diseases and critical care. The company specializes in providing new therapies for intensive care medicine and rare diseases. AOP Health aims to serve healthcare providers and patients in need of innovative medical solutions. With a commitment to science and trust, AOP Health continues to expand its global reach in the healthcare sector.Explore more
Popular SearchesAOP OrphanAOP Orphan Pharmaceuticals AGAOP Orphan PharmaceuticalsAOP Orphan-developedAOP Orphan InternationalSIC Code 28,283NAICS Code 32,325Show moreAOP Orphan Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AOP Orphan your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
AOP Orphan, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at AOP Orphan
Click to see if AOP Orphan had a recent Job posting/layoffs
Check if AOP Orphan has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on AOP Orphan recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once AOP Orphan has new funding data
Product Launch: Get notified when AOP Orphan launches new products
Check out if AOP Orphan is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
AOP Orphan is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AOP Orphan is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AOP Orphan.
AOP Orphan Tech Stack
A closer look at the technologies used by AOP Orphan
Most Recent Scoops
Project
A front-line source has indicated that the organization is prioritizing quality management system (QMS) efforts over the next three months.
Quality Management
Project
A front-line source in legal has indicated that the organization has completed initiatives related to risk management & analytics within the last nine months.
Analytics & Insights
Project
A front-line source in legal has indicated that the organization has completed initiatives related to data privacy within the last nine months.
Information Security
Project
A front-line source in legal has indicated that the organization is planning to begin initiatives related to document drafting solutions software within three to six months. AOP Orphan is expected to use a contingent workforce to support these efforts.
Contingent Workforce, Document Management, Software
Project
Legal Affairs, Software
AOP Orphan News & Media
BESREMi® (Ropeginterferon alfa-2b) approved by the US FDA
VIENNA--(BUSINESS WIRE)-- #aoporphan--In 2009, AOP Orphan in-licensed the exclusive rights for clinical development and commercialization of Ropeginterferon alfa-2b in Polycythaemia Vera (PV), a rare disease, and other myeloproliferative neoplasms (MPNs) for European, Commonwealth of Independent States (CIS), and Middle Eastern markets. Based on a pivotal study development program, which included the studies PEGINVERA, PROUD-PV and CONTINUATION-PV the European Medicines Agency (EMA) authorized BEagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (“AOP Orphan”), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AOP Orphan
Sign Up For FreeTo access detailed company insights
AOP Health is a European pioneer in integrated therapies for rare diseases and critical care. The company specializes in providing new therapies for intensive care medicine and rare diseases. AOP Health aims to serve healthcare providers and patients in need of innovative medical solutions. With a commitment to science and trust, AOP Health continu... Read More
